Information Provided By:
Fly News Breaks for January 15, 2019
INCY
Jan 15, 2019 | 06:05 EDT
Goldman Sachs analyst Salveen Richter added Incyte to his firm's Americas Conviction List and boosted his price target for the shares to $111 from $102. He keeps a Buy rating on the name. At current share levels, Incyte provides "pipeline and M&A optionality in the context of a solid commercial franchise," Richter tells investors in a research note. He points out the company's pipeline consists of 21 drugs across the verticals of oncology and inflammation/autoimmunity.
News For INCY From the Last 2 Days
There are no results for your query INCY